Oncolytic HSV and Erlotinib Inhibit Tumor Growth and Angiogenesis in a Novel Malignant Peripheral Nerve Sheath Tumor Xenograft Model

This publication has 41 references indexed in Scilit:

• Second Primary Tumors in Neurofibromatosis 1 Patients Treated for Optic Glioma: Substantial Risks After Radiotherapy
  Journal of Clinical Oncology, 2006
• Degradation of Fibrillar Collagen in a Human Melanoma Xenograft Improves the Efficacy of an Oncolytic Herpes Simplex Virus Vector
  Cancer Research, 2006
• Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
  New England Journal of Medicine, 2005
• Epidermal Growth Factor Receptor, Protein Kinase B/Akt, and Glioma Response to Erlotinib
  JNCI Journal of the National Cancer Institute, 2005
• Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
  PLoS Medicine, 2005
• Targeting neovascular pericytes in neurofibromatosis type 1
  Angiogenesis, 2004
• Oncolytic herpes simplex virus mutants are more efficacious than wild‐type adenovirus Type 5 for the treatment of high‐risk neuroblastomas in preclinical models
  Pediatric Blood & Cancer, 2004
• Neoadjuvant treatment of hepatic malignancy: an oncolytic herpes simplex virus expressing IL-12 effectively treats the parent tumor and protects against recurrence-after resection
  Cancer Gene Therapy, 2003
• Tumor Growth Inhibition by Intratumoral Inoculation of Defective Herpes Simplex Virus Vectors Expressing Granulocyte–Macrophage Colony-Stimulating Factor
  Molecular Therapy, 2000
• Angiogenic and invasive properties of neurofibroma Schwann cells.
  The Journal of cell biology, 1990